Pharmaceutical Mail. Carlos Bañado, General Director of Mabxience, explains that this concept refers to the fact that the variations between the biosimilar and the reference biologic are in the same range as those of the different batches of the innovator.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
